|
| 37400643 | Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. | Nat Med | 2024 |
| 37699031 | Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. | Neuro Oncol | 2024 |
| 38049623 | Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2024 |
| 36843451 | Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. | Neuro Oncol | 2023 |
| 36367837 | Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. | Neuro Oncol | 2023 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 35994777 | National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. | Neuro Oncol | 2023 |
| 35917833 | Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study. | Neuro Oncol | 2023 |
| 36402744 | Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. | Neuro-Oncology | 2023 |
| 36254884 | Negative trials over and over again: How can we do better? | Neuro-Oncology | 2023 |
| 37853118 | Clinical trial links oncolytic immunoactivation to survival in glioblastoma. | Nature | 2023 |
| 37672566 | Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. | | 2023 |
| 37935104 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37812369 | Molecular Profiling and Targeted Therapies in Gliomas. | | 2023 |
| 37722087 | Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. | J Clin Oncol | 2023 |
| 37573572 | Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. | Acta Neuropathol | 2023 |
| 38071654 | Defining interventions and metrics to improve diversity in CNS clinical trial participation: a SNO and RANO effort. | | 2023 |
| 37693537 | Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy. | bioRxiv | 2023 |
| 37554224 | Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression. | Neurooncol Adv | 2023 |
| 37870091 | Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors. | | 2023 |
| 37865854 | Novel trial designs in neuro-oncology. | | 2023 |
| 37865722 | Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2023 |
| 36780194 | ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. | Clin Cancer Res | 2023 |
| 37215951 | An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma. | Neurooncol Adv | 2023 |
| 36970171 | The predictive value of partial promoter methylation for IDH-wild-type glioblastoma patients. | | 2023 |
| 37277265 | Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419). | Eur J Cancer | 2023 |
| 37085569 | Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. | Nat Rev Clin Oncol | 2023 |
| 37027809 | Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 37399061 | Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. | Neuro Oncol | 2023 |
| 37272516 | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. | N Engl J Med | 2023 |
| 37268724 | Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. | Nat Med | 2023 |
| 36823302 | Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. | Nat Med | 2023 |
| 36494005 | Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. | Ann Oncol | 2023 |
| 37327319 | Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients. | Clin Cancer Res | 2023 |
| 37260393 | A genomic score to predict local control among patients with brain metastases managed with radiation. | Neuro Oncol | 2023 |
| 36634606 | NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. | J Natl Compr Canc Netw | 2023 |
| 36632791 | EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. | Neuro Oncol | 2023 |
| 36939557 | Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. | Clin Cancer Res | 2023 |
| 36694348 | Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. | Neuro Oncol | 2023 |
| 37059834 | Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. | Nat Med | 2023 |
| 37306665 | Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis. | | 2023 |
| 36617262 | Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. | Neuro Oncol | 2023 |
| 37167580 | Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along. | | 2023 |
| 37167013 | Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. | Neuro Oncol | 2023 |
| 36990614 | Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. | Lancet Oncol | 2023 |
| 36848613 | Validation of Predictive Analyses for Interim Decisions in Clinical Trials. | | 2023 |
| 37540556 | Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. | Clin Cancer Res | 2023 |
| 37503808 | Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology. | | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |